Sermorelin Side Effects: Is Sermorelin Safe?

The short answer

Sermorelin has a mild side-effect record. When it was an FDA-approved drug (Geref), the most common problem was brief pain, redness or swelling at the injection site, in about 16% of children treated. Flushing, headache and dizziness each affected under 1%. The open questions are long-term: no trial ran past four months in healthy adults.

Is sermorelin safe?

For short-term use under a prescriber, the record is reassuring. Sermorelin was approved in the U.S. twice, as a one-time diagnostic test in 1990 and as a daily treatment for children with growth hormone deficiency in 1997¹. The maker stopped selling both in 2008, and in 2013 FDA formally determined that Geref was not withdrawn for reasons of safety or effectiveness¹.

Two caveats matter more than the side-effect list:

• •What you buy today is not Geref. Telehealth sermorelin is compounded. FDA states that compounded drugs are not FDA-approved and are not checked for safety, effectiveness or quality before sale³. The quality of your vial depends on the pharmacy that made it.
• •The long-term question is open. The safety data come from short courses: a single diagnostic dose, pediatric treatment, and adult trials of six and sixteen weeks⁴⁵. Nobody has studied years of nightly use in healthy adults chasing anti-aging benefits.

What are the common side effects of sermorelin?

FDA's review of the two Geref products lists the side effects below². The pediatric trials provide the only frequency figures.

Injection-site reactions are the one side effect most people will notice. FDA's review describes them as self-limited and transient. Ask your prescriber about rotating injection sites.

Flushing usually means warmth and redness in the face shortly after a dose. It affected fewer than 1% of children in the pediatric trials.

Antibodies. A significant share of children treated with Geref tested positive at times for antibodies to the drug. FDA's review notes these were not linked to generalized allergic reactions and did not seem to reduce its effect².

What the adult trials add:

• •In the six-week trial of 2 mg nightly in older men, researchers reported no significant adverse effects⁴.
• •In the 16-week trial of a close sermorelin analog in older men and women, the only side effect was a temporary rise in blood lipids that resolved by the end of the study⁵.

Who should not take sermorelin?

Ask your prescriber directly if any of these apply to you. These are the groups where raising growth hormone and IGF-1 is the main concern, not a full list of contraindications:

• •Active cancer or a recent cancer history. Growth hormone and IGF-1 drive cell growth (see the cancer question below).
• •Pregnancy or breastfeeding. Sermorelin was never studied in these groups for this use.
• •Diabetes or prediabetes. Growth hormone tends to raise blood sugar. Growth hormone itself raised the rate of impaired fasting glucose in healthy older adults⁶.
• •Anyone already using growth hormone or another secretagogue. Stacking compounds that raise the same hormone adds risk with no evidence of extra benefit.

A good telehealth program should ask about all of these during intake. If it does not, consider that a warning sign.

Why was Geref discontinued if it was safe?

Its maker, EMD Serono, told FDA in 2008 that it was discontinuing both Geref products, and FDA withdrew the approvals effective June 2009. In 2013, after a citizen petition, FDA reviewed its files and the postmarketing literature and concluded that neither product was withdrawn for reasons of safety or effectiveness¹. That determination means a generic version could be approved if a company applied. None has been.

So the drug left the market for business reasons, not because it harmed people. The flip side: no company has run modern trials of sermorelin for adults, and it was never approved for anti-aging use.

Does sermorelin cause cancer?

There is no evidence that it does, and no trial was long enough to answer the question.

The concern is based on biology. Sermorelin works by raising growth hormone, which raises IGF-1. In a meta-analysis of 21 studies, people with IGF-1 levels at the high end of normal had a modestly higher risk of prostate cancer and premenopausal breast cancer than those at the low end⁷. That shows an association with natural IGF-1 levels, not proof that raising IGF-1 with a drug causes cancer. But it explains why prescribers screen for cancer history and keep IGF-1 within the normal range.

Aging research adds another concern: across many animal models, lower growth hormone and IGF-1 signaling is linked to longer life, not shorter⁸. That is why we treat sermorelin as a body-composition drug, not a longevity drug. The full argument is in sermorelin for longevity.

Sermorelin vs HGH: which is riskier?

Growth hormone given directly to healthy older adults caused significantly more soft-tissue swelling, joint pain, carpal tunnel syndrome, breast enlargement in men and impaired fasting glucose, in exchange for about 2 kg of lean mass⁶. Sermorelin keeps the pituitary's own feedback loop in charge, which is a real safety advantage. It also produces a smaller effect.

What should you monitor while taking sermorelin?

Sermorelin works through your own hormones, so a few simple checks tell you whether it is doing anything and whether it is safe to continue:

• •IGF-1. This is the clearest sign that sermorelin is working. In the 16-week trial, IGF-1 rose within two weeks and then drifted back toward baseline by week 16⁵. A level that is not rising, or one that goes above the normal range for your age, is worth discussing with your prescriber.
• •Fasting glucose or A1c. Growth hormone tends to push blood sugar up, which is the clearest metabolic risk in the growth hormone data⁶.
• •Lipids. The one adult trial that reported a side effect found a temporary rise in blood lipids⁵.
• •Swelling, joint pain or tingling in the hands. These were the hallmark side effects of growth hormone itself in older adults⁶. They were not reported with sermorelin, but they are the signal to watch if your IGF-1 runs high.

How to lower your risk

• •Ask which pharmacy fills it. Ask whether it is a 503A or 503B pharmacy and in which state it is licensed. Our provider ranking gives credit to providers that name their pharmacy.
• •Get a baseline IGF-1 and recheck it after a few months. A good program will order it or ask for it.
• •Report anything systemic, such as fever, chest tightness or hives, rather than waiting it out.
• •Do not stack sermorelin with other growth hormone releasers without your prescriber's input.

Programs that sell sermorelin, from about $99 to $300 a month, include WellMedr, Strut Health, bmiMD, RNK Health, Gala Health, Luvo Health and Synergy Rx. What to expect and when is in sermorelin before and after. Everything else on sermorelin is on the sermorelin hub, and other options are compared in peptides for longevity. If you are also comparing other compounded injectables, glutathione injections explains why the ingredient grade matters.

The honest summary

In the doses and timeframes that were studied, sermorelin was mild: mostly injection-site reactions, with flushing and headache uncommon. It was not withdrawn for safety reasons. The risks that remain are those nobody has measured: years of use in healthy adults, the long-term IGF-1 question, and the quality of a compounded vial. Your prescriber can help with the first two. Asking about the pharmacy covers the third.